Stratistics MRC에 따르면, 정맥천자 시술 세계 시장은 2025년에 14억 2,000만 달러, 예측 기간 동안 CAGR은 8.0%를 나타내고, 2032년에는 24억 3,000만 달러에 도달할 것으로 예측됩니다.
정맥천자는 바늘로 정맥을 천자하여 혈액을 채취하거나 약제나 수액을 투여하거나 하는 의료치료입니다. 최소한으로 억제하고 합병증을 줄이기 위해 숙련을 필요로 합니다.
2021년에 발표된 미국 질병관리예방센터의 데이터에 따르면 매년 약 80만 5,000명이 이 검사를 받고 있습니다.
만성 질환 증가
당뇨병, 암, 심혈관 질환 등의 만성 질환의 유병률 증가는 정맥천자 시술 수요를 촉진하고 있습니다. 정맥 천자 서비스에 대한 액세스가 크게 개선되었습니다. 이러한 수요 증가는 조기 진단 및 예방 건강 관리를 추진하는 정부 이니셔티브에 의해 더욱 강화되고 있습니다.
훈련된 사혈 전문의 부족
정맥천자 시술 시장은 숙련된 사혈 전문의의 현저한 부족에 의해 억제되고 있습니다. 그 프로그램이나 자격이 없는 것이, 이 문제를 악화시키고 있습니다. 또한, 헬스케어 부문에 있어서의 스탭의 높은 이직율도, 경험 풍부한 전문가의 부족을 조장하고 있습니다.
외래 및 재택치료 서비스 성장
외래 진료 및 재택 건강 서비스에 대한 선호도가 높아짐에 따라 정맥천자 시술 시장에 큰 기회가 생겼습니다. 이 장비의 발전은 이러한 추세를 더욱 강화해 왔으며, 기술의 진보로 기존의 임상 환경 외에도 정확한 정맥천자 시술이 가능해졌습니다.
비침습적 진단에 대한 선호도 증가
비침습적 진단 기술의 인기가 높아짐에 따라 정맥천자 시술 시장에 위협이 됩니다. 이러한 기술은 정맥 천자 중 불안이나 불편함을 경험하는 환자들에게 특히 매력적입니다. 또한, 웨어러블 건강 모니터링 기기의 진보에 의해 빈번한 채혈의 필요성이 감소하고 있습니다.
COVID-19의 영향
COVID-19 팬데믹은 정맥천자 시술 시장에 큰 영향을 미쳤습니다. 팬데믹은 또한 적시 진단 서비스의 중요성을 강조하여 궁극적인 회복으로 이어졌습니다. 팬데믹 후에는 정기적인 건강 진단과 진단에 대한 의식이 높아지면서 성장의 원동력이 될 것으로 예측됩니다.
예측기간 동안 두정맥 부문이 최대가 될 전망
머리 정맥 부문은 채혈에 대한 접근성과 사용 편의성으로 인해 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 질병을 최소화하고 환자의 편안함을 높일 수 있기 때문에 건강 관리 전문가들 사이에서 선호도가 높아지고 있습니다.
예측 기간 동안 병원 부문의 CAGR이 가장 높을 것으로 예상
예측 기간 동안 정맥 천자 서비스의 주요 공급자 역할로 인해 병원 부문이 가장 높은 성장률을 보일 것으로 예측됩니다. 병원 실험실의 첨단 기술과 자동화의 통합은 정맥 천자 프로세스의 정확성과 효율성을 향상시킵니다.
예측 기간 동안 아시아태평양은 급속히 확대되는 건강 관리 인프라로 인해 최대 시장 점유율을 차지할 것으로 예측됩니다. 질병의 조기 발견과 예방 의료를 추진하는 정부의 이니셔티브는 시장의 성장을 더욱 촉진합니다.
예측 기간 동안 북미가 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 이 지역은 광범위한 의료 투자와 연구 개발에 대한 집중력 덕분에 혜택을 누리고 있습니다. 진단 기술과 자동화에 있어서의 기술 혁신은 정맥 천자의 효율적인 실시를 서포트하고 있습니다. 또한, 예방 의료나 정기 검진에 대한 의식의 고조가 시장을 견인하고 있습니다.
According to Stratistics MRC, the Global Venipuncture Procedure Market is accounted for $1.42 billion in 2025 and is expected to reach $2.43 billion by 2032 growing at a CAGR of 8.0% during the forecast period. Venipuncture is a medical procedure that involves puncturing a vein with a needle to withdraw blood or administer medications and fluids. Commonly performed on the arm, it is essential for diagnostic testing, transfusions, and intravenous therapy. The procedure requires skill to ensure minimal discomfort and reduce complications. It is routinely conducted in hospitals, clinics, and laboratories by trained healthcare professionals such as phlebotomists, nurses, or medical technicians.
According to the Centers for Disease Control and Prevention data published in 2021. Every year, about 805,000 people in the U.S. suffered with heart attack and about 1 in 20 adults aged 20 and older have coronary artery disease (CAD).
Rising prevalence of chronic diseases
The increasing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular conditions, is driving the demand for venipuncture procedures. Chronic diseases often require routine blood tests for diagnosis, treatment monitoring, and management, thus boosting the market. With advancements in healthcare infrastructure and diagnostic tools, access to venipuncture services has improved significantly. This growing demand is further supported by government initiatives promoting early diagnosis and preventive healthcare. Additionally, an aging population prone to chronic conditions adds to the necessity of venipuncture services.
Shortage of trained phlebotomists
The venipuncture procedure market is restrained by a notable shortage of skilled phlebotomists. Properly trained personnel are crucial to ensure safe and effective blood collection, minimizing the risk of errors and patient discomfort. The lack of adequate training programs and certifications in many regions exacerbates this issue. Moreover, high staff turnover in the healthcare sector contributes to the scarcity of experienced professionals. This challenge is particularly pronounced in rural and underdeveloped areas, where healthcare resources are limited.
Growth in outpatient and home care services
The increasing preference for outpatient care and home healthcare services presents a significant opportunity for the venipuncture procedure market. These settings offer convenience, reduced costs, and enhanced patient comfort, driving their adoption. The expansion of point-of-care testing and portable diagnostic devices further supports this trend. Advances in technology enable precise venipuncture procedures outside traditional clinical environments. Moreover, the rising demand for personalized healthcare solutions aligns with the growth of these services.
Rising preference for non-invasive diagnostic alternatives
The growing popularity of non-invasive diagnostic techniques poses a threat to the venipuncture procedure market. Methods such as saliva, urine, and breath tests offer a less invasive and more patient-friendly alternative to blood collection. These technologies are particularly appealing to patients who experience anxiety or discomfort during venipuncture. Additionally, advancements in wearable health monitoring devices are reducing the need for frequent blood draws. As these alternatives become more accessible and reliable, they may displace traditional venipuncture procedures.
Covid-19 Impact
The COVID-19 pandemic significantly impacted the venipuncture procedure market. During the initial phases, lockdowns and healthcare system disruptions led to a decline in non-urgent blood tests and diagnostics. However, the pandemic also highlighted the importance of timely diagnostic services, leading to an eventual recovery. Post-pandemic, heightened awareness about regular health check-ups and diagnostics is expected to drive growth. The pandemic underscored the critical role of venipuncture in healthcare, reinforcing its importance in the long term.
The cephalic vein segment is expected to be the largest during the forecast period
The cephalic vein segment is expected to account for the largest market share during the forecast period, due to its accessibility and ease of use for blood collection. This vein is commonly chosen for venipuncture procedures, especially in outpatient and emergency settings. Its prominent location minimizes complications and enhances patient comfort, increasing its preference among healthcare professionals. Additionally, the growing demand for routine diagnostics and chronic disease monitoring further drives the utilization of cephalic vein.
The hospitals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, due to their role as primary providers of venipuncture services. Hospitals handle a high volume of diagnostic and therapeutic procedures requiring blood collection, driving their market share. The integration of advanced technologies and automation in hospital labs enhances the accuracy and efficiency of venipuncture processes. Additionally, hospitals' ability to cater to complex cases and emergency situations positions them as key players in the market.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its rapidly expanding healthcare infrastructure. The region's large population and increasing prevalence of chronic diseases drive the demand for venipuncture procedures. Government initiatives promoting early disease detection and preventive care further enhance market growth. Additionally, rising disposable incomes and improved access to healthcare services contribute to increased diagnostic activities.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to its advanced healthcare systems and high diagnostic test volumes. The region benefits from extensive healthcare investments and a strong focus on research and development. Innovations in diagnostic technologies and automation support the efficient conduct of venipuncture procedures. Moreover, increasing awareness about preventive healthcare and routine check-ups drives the market.
Key players in the market
Some of the key players profiled in the Venipuncture Procedure Market include Becton, Dickinson and Company (BD), Terumo Corporation, Quest Diagnostics, Greiner Bio-One International, Fresenius Kabi AG, AccuVein Inc., Smiths Medical, B. Braun Medical, Christie Medical Holdings, Inc., TransLite, LLC, Sharn Anesthesia, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific, BioReference Health, LLC, and UNILABS.
In April 2025, BD announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasix(TM) ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.
In March 2025, Terumo Vietnam Medical Equipment and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) to collaborate on advancing cardiovascular expertise in Vietnam. The initiative aims to support healthcare professionals in updating their knowledge and skills in interventional cardiology.